Emergencies in dermatology: diagnosis, classification and therapy

References

• Gertsch WJ. The spider genus Loxosceles in South America (Araneae, Scytodidae). Bull. Am. Mus. Nat. Hist.136, 117–174 (1967).
   Google Scholar
• da Silva PH, da Silveira RB, Appel MH, Mangili OC, Gremski W, Veiga SS. Brown spiders and loxoscelism. Toxicon44, 693–709 (2004).
   PubMed Web of Science ®Google Scholar
• Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Ann. Emerg. Med.30, 28–32 (1997).
   PubMed Web of Science ®Google Scholar
• Rees R, Campbell D, Rieger E, King LE. The diagnosis and treatment of brown recluse spider bites. Ann. Emerg. Med.16, 945–949 (1987).
   PubMed Web of Science ®Google Scholar
• Sams HH, Dunnick CA, Smith ML, King LE Jr. Necrotic arachnidism. J. Am. Acad. Dermatol.44, 561–576 (2001).
   PubMed Web of Science ®Google Scholar
• Gertsch WJ, Ennik F. The spider genus Loxosceles in North America, Central America and the West Indies (Araneae, Loxoscelidae). Bull. Am. Mus. Nat. Hist.175, 264–360 (1983).
   Web of Science ®Google Scholar
• Wong RC, Hughes SE, Voorhees JJ. Spider bites. Arch. Dermatol.123, 98–104 (1987).
   PubMed Web of Science ®Google Scholar
• Caveness WA. Insect bite, complicated with fever. Nashville J. Med. Surg.10, 333 (1872).
   Google Scholar
• Hogan CJ, Barbaro KC, Winkel K. Loxoscelism: old obstacles, new directions. Ann. Emerg. Med.44, 608–624 (2004).
   PubMed Web of Science ®Google Scholar
• Isbister GK, White J. Clinical consequences of spider bites: recent advances in our understanding. Toxicon43, 477–492 (2004).
   PubMed Web of Science ®Google Scholar
• Heitz JR, Norment BR. Characteristics of alkaline phosphatase activity in brown recluse venom. Toxicon12, 181–187 (1974).
   PubMed Web of Science ®Google Scholar
• Geren CR, Chan TK. Howell DE, Odell GV. Isolation and characterization of toxins from brown recluse spider venom (Loxosceles reclusa). Arch. Biochem. Biophys.174, 90–99 (1976).
   PubMed Web of Science ®Google Scholar
• Rekow MA, Civello DJ, Geren CR. Enzymatic and hemolytic properties of brown recluse spider (Loxosceles reclusa) toxin and extracts of venom apparatus, cephalothorax abdomen. Toxicon21, 441–444 (1983).
   PubMed Web of Science ®Google Scholar
• Forrester LJ, Barrett JT, Campbell BJ. Red blood cell lysis induced by the venom of the brown recluse spider: the role of sphingomyelinase D. Arch. Biochem. Biophys.187, 355–365 (1978).
   PubMed Web of Science ®Google Scholar
• Kurpiewski G, Forrester L, Burrett J, Campbell BJ. Platelet aggregation and sphingomyelinase D activity of purified toxin from the venom of Loxosceles reclusa. Biochem. Biophys. Acta678, 467–476 (1981).
   PubMedGoogle Scholar
• Futrell JM. Loxoscelism. Am. J. Med. Sci.304, 261–267 (1992).
   PubMed Web of Science ®Google Scholar
• Alario A, Price G, Stahl R, Bancroft P. Cutaneous necrosis following a spider bite: a case report and review. Pediatrics79, 618–621 (1987).
   PubMed Web of Science ®Google Scholar
• Gross AS, Wilson DC, King LE. Persistent segmental cutaneous anesthesia after a brown recluse spider bite. South Med. J.83, 1321–1323 (1990).
   PubMed Web of Science ®Google Scholar
• Málaque CMS, Castro-Valencia JE, Cardoso JLC, Franca FOS, Barbaro KC, Fan HW. Clinical and epidemiological features of definitive and presumed Loxoscelism in Saõ Paulo, Brazil. Rev. Inst. Med. Trop. Sao Paulo44, 139–143 (2002).
   PubMedGoogle Scholar
• King LE, Rees RS. Treatment of brown recluse spider bite. J. Am. Acad. Dermatol.14, 691–692 (1986).
   PubMed Web of Science ®Google Scholar
• Nance WE. Hemolytic anemia of necrotic arachnoidism. Am. J. Med.31, 801 (1961).
   PubMed Web of Science ®Google Scholar
• Taylor EH, Denny WF. Hemolysis, renal failure and death, presumed secondary to bite of brown recluse spider. South Med. J.58, 1209–1211 (1966).
   Google Scholar
• Vorse H, Seccareccio P, Woodruff K, Humphrey GB. Disseminated intravascular coagulopathy following fatal brown spider bite (necrotic arachnidism). J. Pediatr.80, 1035–1037 (1972).
   PubMed Web of Science ®Google Scholar
• Lane DR, Youse JS. Coombs-positive hemolytic anemia secondary to brown recluse spider bite: a review of the literature and discussion of treatment. Cutis74, 341–347 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez H, Golan H, Gat A, Brenner S. Id reaction to spider bite. J. Am. Acad. Dermatol.548, 53 (2005).
   Google Scholar
• Trattner A, Ingber A, Cleper R, Weisman-Katzenelson V, Sandbank M. A pustular form of loxoscelism (bite of the brown recluse spider). Hautarzt41, 218–219 (1990).
   PubMed Web of Science ®Google Scholar
• Davidovici B, Dyachenko P, Cagnano E, Rozenman D, Halevy S, EuroSCAR; RegiSCAR study group. Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases. J. Am. Acad. Dermatol.55, 525–529 (2006).
   PubMed Web of Science ®Google Scholar
• Dillaha CJ, Jansen GT, Honeycutt WM, Hayden CR. North American loxoscelism: necrotic bite of the brown recluse spider. JAMA188, 153–156 (1964).
   Web of Science ®Google Scholar
• Sezertno UM, Zannin M, Coelho LK et al. A clinical and epidemiological study of Loxosceles spider envenoming in Santa Catarina, Brazil. Trans. R. Soc. Trop. Med. Hyg.92, 546–548 (1998).
   PubMed Web of Science ®Google Scholar
• Cole HP, Wesley RE, King LE. Brown recluse spider envenomation of the eyelid: an animal model. Ophthal. Plast. Reconstr. Surg.11, 153–164 (1995).
   PubMed Web of Science ®Google Scholar
• Morgan BB. Lysis of human erythrocytes by venom from the brown recluse spider, Loxosceles reclusa. Toxicon16, 85–88 (1978).
   PubMed Web of Science ®Google Scholar
• Berger RS. A critical look at therapy for the brown recluse spider bite. Arch. Dermatol.107, 298 (1973).
   PubMedGoogle Scholar
• Wilson DC, King LE. Spiders and spider bites. Dermatol. Clin.8, 277–286 (1990).
   PubMed Web of Science ®Google Scholar
• Isbister GK. Necrotic arachnidism: the mythology of a modern plague. Lancet364, 549–553 (2004).
   PubMed Web of Science ®Google Scholar
• Wasserman GS, Anderson PS. Loxoscelism and necrotic arachnidism. J. Toxicol. Clin. Toxicol.21, 451–472 (1984).
   Web of Science ®Google Scholar
• Vetter R. Myth: idiopathic wounds are often due to brown recluse or other spider bites throughout the United States. West. J. Med.173, 357–358 (2000).
   PubMedGoogle Scholar
• Osterhoudt KC. Diagnosis of brown recluse spider bites in absence of spiders. Clin. Pediatr. (Phila)43, 407 (2004).
   PubMedGoogle Scholar
• Roche KJ, Chang MW, Lazarus H. Cutaneous anthrax infection. N. Engl. J. Med.345, 1611 (2001).
   PubMed Web of Science ®Google Scholar
• Gomez HF, Krywko DM, Stoecker WV. A new assay for the detection of Loxosceles species (brown recluse) spider venom. Ann. Emerg. Med.39, 469–474 (2002).
   PubMed Web of Science ®Google Scholar
• Stoecker WV, Green JA, Gomez HF. Diagnosis of loxoscelism in a child confirmed with an enzyme-linked immunosorbent assay and noninvasive tissue sampling. J. Am. Acad. Dermatol.55, 888–890 (2006).
   PubMed Web of Science ®Google Scholar
• Leach J, Bassichis B, Itani K. Brown recluse spider bites to the head: three cases and a review. Ear Nose Throat J.83, 465–470 (2004).
   PubMedGoogle Scholar
• Litovitz TL, Klein-Schwartz W, Dyer KS, Shannon M, Lee S, Powers M. Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med.16, 443–497 (1998).
   PubMed Web of Science ®Google Scholar
• Anonymous Necrotic arachnidism-Pacific northwest,1988–1996. MMWR Morb. Mortal. Wky. Rep.45, 433–436 (1996).
   PubMedGoogle Scholar
• King LE. Brown recluse spider bites: stay cool (Letter). JAMA254, 2895–2896 (1985).
   PubMed Web of Science ®Google Scholar
• Monteiro CL, Rubel R, Cogo LL, Mangili OC, Gremski W, Veiga SS. Isolation and identification of Clostridium perfringes in the venom and fangs of Loxosceles intermedia (brown spider): enhancement of the dermonecrotic lesion in loxoscelism. Toxicon40, 409–418 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson PC. Necrotizing spider bites. Am. Fam. Physician.26, 198–203 (1982).
   PubMed Web of Science ®Google Scholar
• Thuong-Nguyen V, Kadunce D, Hendrix J, Gammon W, Zone J. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J. Invest. Dermatol.100, 349–355 (1993).
   PubMed Web of Science ®Google Scholar
• Booth S, Moody C, Dahl M, Herron M, Nelson R. Dapsone suppresses integrin-mediated neutrophil adherence function. J. Invest. Dermatol.98, 135–140 (1992).
   PubMed Web of Science ®Google Scholar
• Debol S, Herron M, Nelson R. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transdaction. J. Leukoc. Biol.62, 827–836 (1997).
   PubMed Web of Science ®Google Scholar
• Barrett SM, Romine-Jenkins M, Fisher DE. Dapsone or electric shock therapy of brown recluse spider envenomation? Ann. Emerg. Med.24, 21–25 (1994).
   PubMed Web of Science ®Google Scholar
• Phillips S, Kohn M, Baker D et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann. Emerg. Med.25, 363–368 (1995).
   PubMed Web of Science ®Google Scholar
• Rees RS, Altenbern DP, Lynch JB, King LE Jr. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann. Surg.202, 659–663 (1985).
   PubMed Web of Science ®Google Scholar
• Elston DM, Miller SD, Young RJ et al. Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: a double-blind, controlled study in a rabbit model. Arch. Dermatol.141, 595–597 (2005).
   PubMedGoogle Scholar
• Mold JW, Thompson DM. Management of brown recluse spider bites in primary care. J. Am. Board. Fam. Pract.17, 347–352 (2004).
   PubMedGoogle Scholar
• Masters EJ, Sams H, King LE Jr. Loxoscelism. The author reply. N. Engl. J. Med.339, 1945–1946 (1998).
   Google Scholar
• Barbaro KC, Cardoso JLC. Mecanismo de açaõ do veneno de Loxosceles e aspectos clinicos do loxoscelismo. In: Animais Peçonhentos No Brasil: Biologia, Cl‎ínica e Terapê Utica Dos Acidentes. Cardoso JLC, Franca FOS, Fan HW, Málaque CMS, Haddad V Jr (Eds). Sarvier, Saõ Paulo, Brasil, 160–174 (2003).
   Google Scholar
• Guilherme P, Fernandes I, Barbaro KC. Neutralization of dermonecrotic and lethal activities and differences among 32–35 kDa toxins of medically important Loxosceles spider venoms in Brazil revealed by monoclonal antibodies. Toxicon39, 1333–1342 (2001).
   PubMed Web of Science ®Google Scholar
• Isbister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. Clin. Toxicol.41, 291–300 (2003).
   Web of Science ®Google Scholar
• Rees R, Shack RB, Withers E, Madden J, Franklin J, Lynch JB. Management of the brown recluse spider bite. Plast. Reconstr. Surg.68, 768–773 (1981).
   PubMed Web of Science ®Google Scholar
• Dyachenko P, Ziv M, Rozenman D. Epidemiological and clinical manifestations of patients hospitalized with brown recluse spider bite. J. Eur. Acad. Dermatol. Venereol.20, 1121–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Delozier JB, Reaves L, King LE, Rees RS. Brown recluse spider bites of the upper extremity. South Med. J.81, 181–184 (1988).
   PubMed Web of Science ®Google Scholar
• Lyell A. Toxic epidermal necrolysis. Lancet1, 1155 (1969).
   PubMedGoogle Scholar
• Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am. J. Dis. Child.24, 526–533 (1922).
   Google Scholar
• Thomas BA. The so-called Stevens–Johnson syndrome. Br. Med. J.1, 1393–1397 (1950).
   PubMedGoogle Scholar
• Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol.68, 355–361 (1956).
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of Toxic Epidermal Necrolysis, Stevens–Johnson Syndrome, and Erythema Multiforme. Arch. Dermatol.129, 92–96 (1993).
   PubMed Web of Science ®Google Scholar
• Wolf R, Matz H, Orion E, Ruocco E, Ruocco V. Targeting the target lesions. Skinmed4, 311–312 (2005).
   PubMedGoogle Scholar
• Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France. 1981–1985. Arch. Dermatol.126, 37–42 (1990).
   PubMed Web of Science ®Google Scholar
• Rasmussen J. Toxic epidermal necrolysis. Med. Clin. North. Am.64, 901–920 (1980).
   PubMed Web of Science ®Google Scholar
• Chosidow O, Delchier JC, Chaumette MT et al. Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet337, 928 (1991).
   PubMed Web of Science ®Google Scholar
• Timsit JF, Mion G, Rouyer N, Le Gulluche Y, Carsin H. Bronchopulmonary distress associated with toxic epidermal necrolysis. Intensive Care. Med.18, 42–44 (1992).
   PubMed Web of Science ®Google Scholar
• Cohen AD, Cagnano E, Halevy S. Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis. Int. J. Dermatol.40, 458–461 (2001).
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature428, 486 (2004).
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA102, 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet359, 727–732 (2002).
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA101, 4180–4185 (2004).
   PubMed Web of Science ®Google Scholar
• Lonjou C, Thomas L, Borot N et al. A marker for Stevens–Johnson syndrome: ethnicity matters. Pharmacogenomics J.6, 265–268 (2006).
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. Med.333, 1600–1607 (1995).
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med.331, 1272–1285 (1994).
   PubMed Web of Science ®Google Scholar
• Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case–control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet353, 2190–2194 (1999).
   PubMed Web of Science ®Google Scholar
• Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J. Am. Acad. Dermatol.56, 181–200 (2007).
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell88, 355–365 (1997).
   PubMed Web of Science ®Google Scholar
• Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science282, 490–493 (1998).
   PubMed Web of Science ®Google Scholar
• Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch. Dermatol.139, 33–36 (2003).
   PubMedGoogle Scholar
• Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr. Opin. Allergy. Clin. Immunol.3, 269–274 (2003).
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet352, 1586–1589 (1998).
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol.136, 323–327 (2000).
   PubMed Web of Science ®Google Scholar
• McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast. Reconstr. Surg.102, 1018–1022 (1998).
   PubMed Web of Science ®Google Scholar
• Demling RH, Ellerbe S, Lowe NJ. Burn unit management of toxic epidermal necrolysis. Arch. Surg.113, 758–759 (1978).
   PubMedGoogle Scholar
• Ohlenschlaeger K. Toxic epidermal necrolysis and Stevens–Johnson’s disease. Acta Derm. Venereol.46, 204–209 (1966).
   PubMedGoogle Scholar
• Patterson R, Dykewicz MS, Gonzalzles A et al. Erythema multiforme and Stevens–Johnson syndrome. Descriptive and therapeutic controversy. Chest98, 331–336 (1990).
   PubMed Web of Science ®Google Scholar
• Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens–Johnson syndrome and toxic epidermal necrolysis in children. J. Pediatr.115, 881–887 (1989).
   PubMed Web of Science ®Google Scholar
• Cheriyan S, Patterson R, Greenberger PA, Grammer LC, Latall J. The outcome of Stevens–Johnson syndrome treated with corticosteroids. Allergy Proc.16, 151–155 (1995).
   PubMedGoogle Scholar
• Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann. Surg.204, 503–512 (1986).
   PubMed Web of Science ®Google Scholar
• Jones WG, Halebian P, Madden M, Finkelstein J, Goodwin CW. Drug-induced toxic epidermal necrolysis in children. J. Pediatr. Surg.24, 167–170 (1989).
   PubMed Web of Science ®Google Scholar
• Kelemen JJ 3rd, Cioffi WG, McManus WF, Mason AD Jr, Pruitt BA Jr. Burn center care for patients with toxic epidermal necrolysis. J. Am. Coll. Surg.180, 273–278 (1995).
   PubMed Web of Science ®Google Scholar
• Sheridan RL, Weber JM, Schulz JT, Ryan CM, Low HM, Tompkins RG. Management of severe toxic epidermal necrolysis in children. J. Burn. Care. Rehabil.20, 497–500 (1999).
   PubMedGoogle Scholar
• Wolf R, Ruocco V, Jablonska S. Treatment of toxic epidermal necrolysis syndrome with ‘disease-modifying’ drugs: the controversy goes on. Clin. Dermatol.22, 267–269 (2004).
   PubMed Web of Science ®Google Scholar
• Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J. Burn. Care. Rehabil.25, 81–88 (2004).
   PubMedGoogle Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol.115, 149–153 (2000).
   PubMed Web of Science ®Google Scholar
• Forman R, Koren G, Shear NH. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years’ experience. Drug Safety25, 965–972 (2002).
   PubMed Web of Science ®Google Scholar
• Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology207, 33–36 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson B. Necrotising fasciitis. Am. Surg.18, 416–431 (1952).
   PubMedGoogle Scholar
• Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fasciitis. Lancet344, 556 (1994).
   PubMed Web of Science ®Google Scholar
• File T, Tan J, Dipersio J. Diagnosing and treating the flesh-eating bacteria syndrome. Cleve. Clin. J. Med.65, 241–249 (1988).
   Google Scholar
• Levine EG, Manders SM. Life-threatening necrotizing fasciitis. Clin. Dermatol.23, 144–147 (2005).
   PubMed Web of Science ®Google Scholar
• Singh G, Sinha SK, Adhikary S, Babu KS, Ray P, Khanna SK. Necrotising infections of soft tissues – a clinical profile. Eur. J. Surg.168, 366–371 (2002).
   PubMedGoogle Scholar
• Elliott DC, Kufera JA, Myers RAM. Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Ann. Surg.224, 672–683 (1996).
   PubMed Web of Science ®Google Scholar
• Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Paediatrics103, E53–E59 (1999).
   Google Scholar
• File T, Tan J. Group A streptococcus necrotizing fasciitis. Compr. Ther.26, 73–81 (2000).
   PubMedGoogle Scholar
• Stevens DL. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shocksyndrome? Clin. Infect. Dis.21, 977–980 (1995).
   PubMed Web of Science ®Google Scholar
• Giuliano A, Lewis F, Hadley K et al. Bacteriology of necrotizing fasciitis. Am. J. Surg.134, 52–57 (1977).
   PubMed Web of Science ®Google Scholar
• Eke N. Fournier’s gangrene: a review of 1726 cases. Br. J. Surg.87, 718–728 (2000).
   PubMed Web of Science ®Google Scholar
• McHenry CR, Piotrowski JJ, Teprinic D, Malangoni MA. Determinants of mortality for necrotizing soft tissue infections. Ann. Surg.221, 558–565 (1995).
   PubMed Web of Science ®Google Scholar
• Riefler JI, Molavi A, Schwartz D, DiNubile M. Necrotizing fasciitis in adults due to group B streptococcus. Report of a case and review of the literature. Arch. Intern. Med.148, 727–729 (1988).
   PubMedGoogle Scholar
• File TM. Necrotizing soft tissue infections. Curr. Infect. Dis. Rep.5, 407–415 (2003).
   PubMedGoogle Scholar
• Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumour necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J. Infect. Dis.165, 879–885 (1992).
   PubMed Web of Science ®Google Scholar
• Cox NH. Streptococcal necrotizing fasciitis and the dermatologist. Br. J. Dermatol.141, 613–616 (1999).
   PubMed Web of Science ®Google Scholar
• Miller LG, Pedreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med.352, 1445–1453 (2005).
   PubMed Web of Science ®Google Scholar
• Rogers RL, Perkins J. Skin and soft tissue infections. Prim. Care33, 697–710 (2006).
   PubMed Web of Science ®Google Scholar
• Liu YM, Chi CY, Ho MW et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J. Microbial. Immunol. Infect.38(6), 430–435 (2005).
   Google Scholar
• Kohler JE, Hutchens MP, Sadow PM, Modi BP, Tavakkolizadeh A, Gates JD. Klebsiella pneumoniae necrotizing fasciitis and septic arthritis: an appearance in the Western hemisphere. Surg. Infect. (Larchmt)8, 227–232 (2007).
   PubMedGoogle Scholar
• Weinberg AN, Swartz MN, Tsao H, Johnson RA. Soft tissue infection. In: Fitzpatrick’s Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF Goldsmith LA, Katz SI (Eds). McGraw–Hill, NY, USA, 1883–1895 (2003).
   Google Scholar
• Laucks SS 2nd. Fournier’s gangrene. Surg. Clin. North. Am.74, 1339–1352 (1994).
   PubMed Web of Science ®Google Scholar
• Salvino C, Harford FJ, Dobrin PB. Necrotizing infections of the perineum. South Med. J.86(8), 908–911 (1993).
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis: the use of frozen-section biopsy. N. Engl. J. Med.310, 1689 (1984).
   PubMed Web of Science ®Google Scholar
• Dahl PR, Perniciaro C, Holmsvist KA, O’Connor MI, Gibson LE. Fulminant group astreptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J. Am. Acad. Dermatol.47, 489–492 (2002).
   PubMed Web of Science ®Google Scholar
• Barker FG, Leppard BJ, Seal DV. Streptococcal necrotizing fasciitis: comparisons between histological and clinical features. J. Clin. Pathol.40, 335–341 (1987).
   PubMed Web of Science ®Google Scholar
• Wykosi MG, Santora TA, Shah RM, Friedman AC. Necrotising fasciitis: CT characteristics. Radiology203, 859–863 (1997).
   PubMed Web of Science ®Google Scholar
• Rahmouni A, Chosidow O, Mathieu D et al. MR imaging in acute infectious cellulitis. Radiology192, 493–496 (1994).
   PubMed Web of Science ®Google Scholar
• Saiag P, Le Breton C, Pavlovic M, Fouchard N, Delzant G, Bigot JM. Magnetic resonance imaging in adults presenting with severe acute infectious cellulitis. Arch. Dermatol.130, 1150–1158 (1994).
   PubMedGoogle Scholar
• Hasham S, Matteucci P, Stanley PRW, Hart NB. Necrotising fasciitis. Br. Med. J.330, 830–833 (2005).
   PubMed Web of Science ®Google Scholar
• Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyberbaric oxygen therapy for necrotising fasciitis reduces mortality and the need for debridements. Surgery108, 847–850 (1990).
   PubMed Web of Science ®Google Scholar
• Lille ST, Sato TT, Engrav LH, Foy H, Jurkovich GJ. Necrotizing soft tissue infections: obstacles in diagnosis. J. Am. Coll. Surg.182, 7–11 (1996).
   PubMed Web of Science ®Google Scholar
• Yong JM. Necrotizing fasciitis. Lancet343, 1427 (1994).
   PubMedGoogle Scholar
• Barry W, Hudgins L, Donta ST et al. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA267, 3315–3316 (1992).
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A, Kaul R, Low DE et al. Plasma from patients with severe group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen induced T-cell proliferation and cytokine expression. J. Immunol.156, 3057–3064 (1996).
   PubMed Web of Science ®Google Scholar
• Voros D, Pissiotis C, Georgantas D, Katsaragakis S, Antoniou S, Papadimitriou J. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br. J. Surg.80, 1190–1191 (1993).
   PubMed Web of Science ®Google Scholar